Medical Director of Lung Innovations Network and The Lung Center at Penn Highlands Healthcare, Sandeep Bansal, M.D., Joins bioAffinity Technologies’ Medical and Scientific Advisory Board and Incorporates CyPath® Lung into Medical Practice
06 Febbraio 2024 - 2:00PM
Business Wire
bioAffinity Technologies, Inc. (Nasdaq: BIAF;
BIAFW), a biotechnology company focused on the need for
noninvasive tests for the detection of early-stage cancer including
CyPath® Lung, today announced that Sandeep Bansal, M.D., Medical
Director of Lung Innovations Network, has joined the Company’s
Medical and Scientific Advisory Board to provide expert advice and
counsel on bioAffinity Technology products and research.
Lung Innovations Network, a patient-centered practice that
offers comprehensive lung care to over 10,000 patients in central
and western Pennsylvania, will incorporate CyPath® Lung into its
practice to aid in the detection of early-stage lung cancer.
“As a clinician, I see hundreds of patients a year who can
directly benefit from CyPath® Lung, bioAffinity’s patient-friendly,
noninvasive test for lung cancer. As a researcher, I am excited
about the Company’s ongoing studies to advance CyPath® Lung, as
well as noninvasive tests for other lung diseases,” Dr. Bansal
said. “I look forward to contributing to bioAffinity’s innovative
approach to lung health by working with the Company’s science team
and the esteemed physicians and researchers who sit on its advisory
board.”
Dr. Bansal has extensive experience in minimally invasive
pulmonary procedures including navigational and robotic
bronchoscopy, endobronchial ultrasound and chest sonography, argon
plasma coagulation, cryotherapy, airway stenting, bronchoscopic
lung volume reduction and indwelling pleural catheters. A principal
investigator of multiple clinical research trials and a journal
reviewer for several medical journals, he has been instrumental in
developing a comprehensive lung center that allows a rapid
assessment and management of healthcare needs based on the
population characteristics and available resources. The model has
been very successful in bringing advanced pulmonary services,
including the latest technology and population health services,
including a robust lung cancer screening program, to support the
region’s clinical needs.
“Dr. Bansal is a highly regarded clinician and researcher who
will be a strong addition to our stellar Medical and Scientific
Advisory Board. His demonstrated commitment to saving lives and
improving patients’ quality of life through innovative therapies
and his prodigious research are truly impressive,” bioAffinity
Technologies President and CEO Maria Zannes said. “The caliber of
our Advisory Board is a testament to the commitment each physician
has placed on bringing breakthrough technology to market in the
battle against lung cancer and other diseases of the lung.”
About CyPath® Lung
CyPath® Lung uses advanced flow cytometry and artificial
intelligence (AI) to identify cell populations in patient sputum
that indicate malignancy. Automated data analysis helps determine
if cancer is present or if the patient is cancer-free. CyPath® Lung
incorporates a fluorescent porphyrin, TCPP, that is preferentially
taken up by cancer and cancer-related cells. Clinical study results
demonstrated that CyPath® Lung had 92% sensitivity, 87% specificity
and 88% accuracy in detecting lung cancer in patients at high risk
for the disease who had small lung nodules less than 20
millimeters. Diagnosing and treating early-stage cancer can improve
outcomes and increase patient survival.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for
noninvasive diagnosis of early-stage cancer and diseases of the
lung and broad-spectrum cancer treatment. The Company’s first
product, CyPath® Lung, is a noninvasive test for the detection of
early-stage lung cancer. CyPath® Lung is marketed as a Laboratory
Developed Test (LDT) by Precision Pathology Laboratory Services, a
subsidiary of bioAffinity Technologies, Inc. For more information,
visit www.bioaffinitytech.com and follow us on LinkedIn, Facebook
and X (Twitter).
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. These forward-looking
statements are based upon current estimates and assumptions and
include statements regarding Dr. Bansal’s contributions to the
Company . These forward-looking statements are subject to various
risks and uncertainties, many of which are difficult to predict
that could cause actual results to differ materially from current
expectations and assumptions from those set forth or implied by any
forward-looking statements. Important factors that could cause
actual results to differ materially from current expectations
include, among others, Dr. Bansal’s ability to make contributions
to the Company and the other factors discussed in the Company’s
Annual Report on Form 10-K for the year ended December 31, 2022,
and its subsequent filings with the SEC, including subsequent
periodic reports on Forms 10-Q and 8-K. Such forward-looking
statements are based on facts and conditions as they exist at the
time such statements are made and predictions as to future facts
and conditions. While the Company believes these forward-looking
statements are reasonable, readers of this press release are
cautioned not to place undue reliance on any forward-looking
statements. The information in this release is provided only as of
the date of this release, and the Company does not undertake any
obligation to update any forward-looking statement relating to
matters discussed in this press release, except as may be required
by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240206573251/en/
Lung Innovations Network Dawn Jeannerat Vice President of
Operations djeannerat@lunginnovations.com
bioAffinity Technologies Julie Anne Overton Director of
Communications jao@bioaffinitytech.com
Investor Relations Dave Gentry RedChip Companies Inc.
1-800-RED-CHIP (733-2447) Or 407-491-4498 BIAF@redchip.com
Grafico Azioni bioAffinity Technologies (NASDAQ:BIAF)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni bioAffinity Technologies (NASDAQ:BIAF)
Storico
Da Set 2023 a Set 2024